肾皮质坏死 中国就医指南

Renal cortical necrosis (RCN) is a rare, severe form of acute kidney injury characterized by ischemic infarction and coagulative necrosis of the renal cortex, while the medulla typically remains relatively spared. Unlike typical acute tubular necrosis, RCN involves irreversible structural damage to the outer renal parenchyma due to profound, sustained disruption of cortical blood flow—most commonly resulting from catastrophic microvascular thrombosis or prolonged vasospasm in the afferent arterioles and intracortical arteries. Pathogenesis centers on a triad of events: (1) severe systemic hypoperfusion or shock (e.g., septic, obstetric, or cardiogenic), (2) activation of the coagulation cascade leading to widespread cortical microthrombi, and (3) failure of autoregulatory mechanisms that normally protect glomerular perfusion. Endothelial injury, complement dysregulation (especially in atypical HUS or preeclampsia-related cases), and cytokine-mediated vasoconstriction further amplify cortical ischemia. Epidemiologically, RCN remains exceedingly rare—accounting for <0.5% of all acute kidney injury admissions globally—with an estimated incidence of 0.01–0.05 per 100,000 person-years. It disproportionately affects critically ill adults, particularly women in the postpartum or late-pregnancy period (historically linked to placental abruption, septic abortion, or severe preeclampsia/eclampsia), though non-obstetric causes—including sepsis, snakebite envenomation, hemolytic uremic syndrome (HUS), malignant hypertension, and major trauma—are increasingly recognized. Key risk factors include prolonged hypotension (<60 mmHg systolic for >1 hour), disseminated intravascular coagulation (DIC), use of vasoconstrictive agents (e.g., ergot alkaloids, NSAIDs in volume-depleted states), preexisting chronic kidney disease, and genetic thrombophilia. Because cortical tissue lacks regenerative capacity, RCN almost invariably leads to permanent loss of nephron mass; over 80% of patients progress to end-stage kidney disease (ESKD) requiring long-term dialysis or transplantation. Quality of life is profoundly impacted: survivors face lifelong dependence on renal replacement therapy, heightened cardiovascular morbidity, recurrent hospitalizations, fatigue, cognitive impairment, sexual dysfunction, and significant psychosocial burden—including anxiety, depression, and reduced employment capacity. Nutritional compromise, bone mineral disorders, and anemia further erode functional independence. Early recognition—via clinical suspicion in high-risk settings, supported by imaging (contrast-enhanced CT showing non-enhancing cortex) and biopsy (though rarely performed acutely due to bleeding risk)—is critical, yet therapeutic options remain largely supportive. Prevention through aggressive hemodynamic stabilization, judicious fluid resuscitation, avoidance of nephrotoxins, and timely obstetric intervention remains the cornerstone of management.

# 肾皮质坏死治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用于早期、局限性坏死且肾功能尚存（eGFR ≥30 mL/min/1.73m²）、无活动性感染或休克者。

• •基础支持：液体复苏、纠正酸中毒、电解质紊乱（Na⁺/K⁺/Ca²⁺监测）；费用：800–2,500元/周（含血气分析、电解质、肌酐动态监测）
• •抗凝/抗血小板：低分子肝素（依诺肝素）+阿司匹林（需排除DIC）；费用：1,200–3,600元/疗程（含凝血四项、D-二聚体、血小板计数）
• •肾脏保护药物：多巴胺微量泵入（仅限血流动力学稳定者）、碳酸氢钠碱化尿液；费用：600–1,800元/周

二、手术/介入治疗方案

适用于进展性少尿/无尿、合并恶性高血压或顽固性容量负荷过重者。

• •连续性肾脏替代治疗（CRRT）：作为桥接支持，为肾组织修复争取时间；费用：12,000–28,000元/周（含滤器、置换液、抗凝监测）
• •肾动脉造影+选择性血管内溶栓/灌注（极少数中心开展）：仅限明确肾动脉分支栓塞且发病＜72小时者；费用：45,000–98,000元/次（含DSA术前检查、造影剂、溶栓药、术后监护）

三、特殊复杂情况处理

晚期广泛坏死（>50%皮质受累）、合并MODS或需长期透析者：

• •过渡至维持性血液透析（HD）或腹膜透析（PD）；首年总费用：HD约12–18万元，PD约10–15万元（含置管、耗材、随访）
• •终末期患者评估肾移植资格；术前评估费：25,000–42,000元（含HLA配型、供受体交叉试验、心肺功能全套）

方案快速选择指南

• •预算有限/轻症：首选保守治疗（总费用≤5,000元/月）
• •中重度急性期：CRRT联合多学科支持（首月预算3–8万元）
• •已进展至ESRD：PD起始更经济，HD更适合高分解代谢者；移植为根治首选（需≥2年透析后评估）